JP7362600B2 - Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物 - Google Patents

Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物 Download PDF

Info

Publication number
JP7362600B2
JP7362600B2 JP2020520532A JP2020520532A JP7362600B2 JP 7362600 B2 JP7362600 B2 JP 7362600B2 JP 2020520532 A JP2020520532 A JP 2020520532A JP 2020520532 A JP2020520532 A JP 2020520532A JP 7362600 B2 JP7362600 B2 JP 7362600B2
Authority
JP
Japan
Prior art keywords
fluoro
phenyl
pyrrolo
dihydro
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536915A (ja
JP2020536915A5 (https=
Inventor
チェン，ホイフェン
ハミルトン，グレゴリー
パテル，スナヘル
ジャオ，グォイリン
ダニエルズ，ブレイク
スティバラ，クレイグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2020536915A publication Critical patent/JP2020536915A/ja
Publication of JP2020536915A5 publication Critical patent/JP2020536915A5/ja
Application granted granted Critical
Publication of JP7362600B2 publication Critical patent/JP7362600B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020520532A 2017-10-11 2018-10-10 Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物 Active JP7362600B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570892P 2017-10-11 2017-10-11
US62/570,892 2017-10-11
PCT/EP2018/077656 WO2019072942A1 (en) 2017-10-11 2018-10-10 BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1

Publications (3)

Publication Number Publication Date
JP2020536915A JP2020536915A (ja) 2020-12-17
JP2020536915A5 JP2020536915A5 (https=) 2021-11-25
JP7362600B2 true JP7362600B2 (ja) 2023-10-17

Family

ID=63840848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520532A Active JP7362600B2 (ja) 2017-10-11 2018-10-10 Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物

Country Status (19)

Country Link
US (1) US11673892B2 (https=)
EP (1) EP3694858B1 (https=)
JP (1) JP7362600B2 (https=)
KR (1) KR20200070297A (https=)
CN (1) CN111201229B (https=)
AU (1) AU2018348930A1 (https=)
BR (1) BR112020007067A2 (https=)
CA (1) CA3078653A1 (https=)
CL (1) CL2020000944A1 (https=)
CO (1) CO2020004977A2 (https=)
CR (1) CR20200151A (https=)
IL (1) IL273443A (https=)
MA (1) MA50356A (https=)
MX (1) MX2020003439A (https=)
PE (1) PE20211246A1 (https=)
PH (1) PH12020550253A1 (https=)
RU (1) RU2020114670A (https=)
SG (1) SG11202003283TA (https=)
WO (1) WO2019072942A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
US11098058B2 (en) * 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
WO2023039795A1 (zh) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Rip1激酶抑制剂及其用途
WO2025261418A1 (zh) * 2024-06-19 2025-12-26 成都赜灵生物医药科技有限公司 并芳基类化合物及其用途
WO2026001865A1 (en) * 2024-06-24 2026-01-02 Sironax Ltd. Rip1 modulators, preparations, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2014518286A (ja) 2011-07-15 2014-07-28 ヤンセン ファーマシューティカルズ，インコーポレーテッド γ−セクレターゼ調節剤としての新規な置換インドール誘導体
WO2017004500A1 (en) 2015-07-02 2017-01-05 Genentech, Inc. Bicyclic lactams and methods of use thereof
WO2017136727A2 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. Compounds, compositions and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
AU8405691A (en) * 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
ES2349762T3 (es) 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP1397364B1 (en) 2001-05-24 2007-07-25 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
NZ578876A (en) 2007-02-07 2012-12-21 Pfizer 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
EP2852584B1 (en) 2012-05-22 2018-02-28 F. Hoffmann-La Roche AG Substituted dipyridylamines and uses thereof
CA2896187A1 (en) 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
PH12019502378A1 (en) 2013-05-01 2022-05-11 Hoffmann La Roche Biheteroaryl compounds and uses thereof
CA2907912A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
WO2016142310A1 (en) 2015-03-09 2016-09-15 F. Hoffmann-La Roche Ag Tricyclic dlk inhibitors and uses thereof
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2014518286A (ja) 2011-07-15 2014-07-28 ヤンセン ファーマシューティカルズ，インコーポレーテッド γ−セクレターゼ調節剤としての新規な置換インドール誘導体
WO2017004500A1 (en) 2015-07-02 2017-01-05 Genentech, Inc. Bicyclic lactams and methods of use thereof
WO2017136727A2 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. Compounds, compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARNISCH, F. et al.，Combined intra-intermolecular criss-cross cycloaddition reactions leading to perfluoroalkylated fused tricyclic nitrogen heterocycles，Journal of fluorine chemistry，2014年，Vol.158，pp.38-43
RACKHAM, D. M.，Spectroscopic studies of some imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives，APPLIED SPECTROSCOPY，1979年，Vol.33, No.6，pp.561-563
REGISTRY[online]，2014.2.16-2017.7.28, [Retrieved on 2022.9.22], Retrieved from：STN,CAS登録番号 2104558-36-1, 1545019-33-7, 1553451-22-1, 1556249-42-3, 1547153-77-4

Also Published As

Publication number Publication date
MX2020003439A (es) 2020-07-29
JP2020536915A (ja) 2020-12-17
SG11202003283TA (en) 2020-05-28
US20200283446A1 (en) 2020-09-10
CL2020000944A1 (es) 2020-08-21
US11673892B2 (en) 2023-06-13
MA50356A (fr) 2021-04-21
CA3078653A1 (en) 2019-04-18
EP3694858B1 (en) 2023-01-11
CR20200151A (es) 2020-05-23
IL273443A (en) 2020-05-31
PH12020550253A1 (en) 2021-02-22
CN111201229B (zh) 2024-08-23
CO2020004977A2 (es) 2020-05-05
KR20200070297A (ko) 2020-06-17
RU2020114670A (ru) 2021-11-12
PE20211246A1 (es) 2021-07-13
CN111201229A (zh) 2020-05-26
EP3694858A1 (en) 2020-08-19
WO2019072942A1 (en) 2019-04-18
AU2018348930A1 (en) 2020-03-26
BR112020007067A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
JP7398391B2 (ja) Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
JP7362600B2 (ja) Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物
JP7734163B2 (ja) 二環式ケトン化合物及びその使用方法
EP3548484A1 (en) Bicyclic amide compounds and methods of use thereof
US20250282788A1 (en) Bicyclic ketone compounds and methods of use thereof
RU2797922C2 (ru) Бициклические кетоны и способы их применения
HK40062362A (en) Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
HK40062362B (en) Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
HK40036919A (en) Compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
HK40017913B (zh) 二环酮化合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211008

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231004

R150 Certificate of patent or registration of utility model

Ref document number: 7362600

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150